We screened 35,001 patients for BCR::ABL1 fusion or JAK2, CALR, or MPL mutations to investigate the sequential development of CML and BCR::ABL1 negative-MPNs. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.